Latest Regulatory Progress News

Australian Rare Earths Limited (ASX – AR3) has made significant strides in advancing its Koppamurra Rare Earths Project, securing pilot-scale processing at ANSTO’s new facility and raising $6 million post-quarter to fund development. Concurrently, promising uranium targets have been identified at its Overland Project.

Talga Group has reported a quarter of significant commercial and regulatory progress, including its largest anode shipment, expanded product offerings, and major mining approvals in Sweden, supported by substantial capital raises and new patents.

Tissue Repair’s December quarter update reveals a cautious path forward for its Phase 3 TR987 trial amid slow patient recruitment, while its TR Pro+ product line gains momentum through a new distributor partnership and upcoming product launches.

Bubs Australia reports a 14% increase in half-year revenue, powered by a 47% jump in US sales, while other regions face challenges. The company remains optimistic about FDA approval and market recovery in H2 FY26.

Cokal Limited has advanced its metallurgical coal operations in Central Kalimantan with new mining contracts, resumed coal shipments, and infrastructure upgrades, aiming for a 2026 production target of approximately 420,000 tonnes.

ReNerve Limited reported a robust 80% increase in quarterly sales driven by strong US market adoption and expanded hospital approvals. The company advances its nerve repair product pipeline with key regulatory milestones and a refreshed board.

ACDC Metals has reported encouraging mineralogy results from its Goschen Central Rare Earth Elements project, reinforcing its strategic value amid rising geopolitical interest. The company maintains a solid cash balance to support ongoing development and exploration activities.

FIN Resources is gearing up to launch its maiden drilling campaign at the high-grade Cabin Lake Gold Project in Canada’s Northwest Territories, with ice road construction starting in early February and drilling expected by March.

Artrya Limited has converted three US foundation partners into commercial customers, generating its first fee-per-scan revenues, while progressing FDA clearance for its Salix Coronary Flow module and expanding its clinical study network.

Imugene Limited has reported compelling clinical trial results for its off-the-shelf CAR T therapy, azer-cel, alongside FDA validation and a strategic collaboration, while managing cash flow amid cost reductions.

Kingsland Minerals has completed a pivotal scoping study for its Leliyn Graphite Project, confirming high-grade purified spherical graphite production potential. The company also secured $2.16 million through a placement and share purchase plan and has commenced a pre-feasibility study.

Terragen Holdings reports a strong quarter with an 87% increase in sales of its ruminant probiotic and advances key livestock and crop trials, positioning itself for expanded market access.